1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C98656BBC51012EC65257F1B003192A3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-role-health-economics-outcomes-research-within-oncology
18
19
2054.90.86.231
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology

ID: 5388


Features:

13 Info Graphics

12 Data Graphics

120+ Metrics

7 Narratives


Pages/Slides: 38


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Medical Affairs' Role in Health Economics & Outcomes Research within Oncology"


STUDY OVERVIEW

As payers and consumers increasingly seek patient outcomes data and clinical evidence supporting the product, biopharmaceutical companies are turning to their medical affairs function to effectively streamline the dissemination of medical information.

Development of strong health outcomes (HO) capabilities within Medical Affairs (MA) organizations requires an increase in MA’s involvement with HO groups, development of field-based HO capabilities, customization of HO data by stakeholders, and building real world data capabilities to generate and utilize HO information.

Best Practices, LLC conducted this study to help companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. This research delivers current data and best practices from Medical Affairs leaders with an oncology focus at top biopharmaceutical companies.

KEY TOPICS

• Longevity of HO Groups
• HO Leadership
• HO Reporting Structure
• HO Group Staffing
• MA’s Role in HO Activities
• MA’s Role in Collecting HO Data
• Utilization of HO Data
• Impact of HO Data on Decisions

KEY METRICS

• Length of Health Outcomes (HO) Programs
• HO Leadership Within Benchmark Class
• Reporting Structure: To whom does the Health Outcomes group(s) report?
• Number of Field and Office Based HO’s FTEs
• Percentage of Field-Based HO FTEs
• Core Field-Based HO Responsibilities
• Medical Affair’s Involvement in HO Activities
• Medical Affair’s Role in Collecting HO Data
• Utilizing the Health Outcomes Data To Inform Patients
• Utilizing the Health Outcomes Data To Inform Payers
• Utilizing the Health Outcomes Data To Inform Providers
• Effect of HO Data on Critical Decisions

SAMPLE KEY FINDINGS

Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class; sixty percent of companies have had it in place for less than three years.

Reporting Structure: 60% of companies’ HO groups report to Medical Affairs. A majority of the interviewed executives think that HO groups must report to a science and research oriented department such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for needs assessment, communicating HO data insights, and interacting with key decision makers.

METHODOLOGY

Best Practices, LLC engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology therapies.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical


Companies Profiled:
Astellas; AstraZeneca; Bayer; Insys Therapeutics; Incyte; Jazz Pharmaceuticals; Lilly; Onyx Pharmaceuticals; ProStrakan; Roche


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.